Agios Pharmaceuticals Inc. (AGIO)
NASDAQ: AGIOHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
AGIO stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.65B
- EPS (TTM)
- -$6.31
- Dividend yield
- None
- 52-week range
- 24.16 – 44.09
- Day range
- 27.43 – 29.14
- Volume / Avg
- 776.16K / 1.06M
- Beta
- —
- Shares outstanding
- 59.81M
52-week range
AGIO stock today
Shares of Agios Pharmaceuticals (AGIO) finished lower on Nov 20 at $27.60, a drop of 4.03% or $1.16 per share, versus the S&P 500's 3.70% decline. At this level, AGIO sits near the bottom of its 52-week range of $24.16 to $44.09: 37.4% below the high, set on Jul 7, 2026 and 14.2% above the low. AGIO is up 1.4% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 9.4%.
Agios Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$6.31), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Agios Pharmaceuticals
Company profileAgios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Brian M. Goff M.B.A.
- Headquarters
- Cambridge, MA
- Employees
- 539
- IPO year
- 2013
- Website
- agios.com
Financial highlights
Full financialsIn fiscal 2025, Agios Pharmaceuticals generated $54.0 million in revenue, up 48.0% from fiscal 2024, its 4th consecutive year of revenue growth. Agios Pharmaceuticals reported a net loss of $412.8 million, compared with net income of $673.7 million a year earlier. Gross margin was 88.3% (down from 88.6%) and operating margin -873.9%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $54.03M | $36.50M | $26.82M | $14.24M | $0 |
| Growth | +48.03% | +36.07% | +88.36% | — | — |
| Net income | $-412.78M | $673.73M | $-352.09M | $-231.80M | $1.60B |
| EPS (diluted) | $-7.12 | $11.64 | $-6.33 | $-4.23 | $26.55 |
Analyst forecast
ForecastConsensus (10 analysts)
buy
Avg. price target
$46.11+67.07%
- Strong buy 0
- Buy 7
- Hold 3
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $-1.09 vs $-1.32
- Surprise
- +17.42%
AGIO news
All AGIO news- Weekly Buzz: RDY, LUPIN, SUNPHARMA Score FDA Wins; AGIO, RARE Slash Jobs; CVS Plots SplitNasdaqABT, AGIO, BEAT, BIOA
- Agios Reports Third Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswire
- Agios Pharmaceuticals Q3 2026 Earnings PreviewSeeking Alpha
- Agios to Highlight Strength and Differentiation of Rare Hematology Portfolio with New Clinical Data for Mitapivat in Sickle Cell Disease and AG-236 in Polycythemia Vera at ASH 2026GlobeNewswire
- Agios Gets New FDA Goal Date For Mitapivat In Sickle Cell DiseaseNasdaqAGIO, HEI.A
- Agios Announces New PDUFA Goal Date of February 1, 2027, for Mitapivat Sickle Cell Disease sNDA; Company Is Launch-Ready and in Labeling Discussions with FDAGlobeNewswire
- Biotech Stocks Facing FDA Decision In November 2026NasdaqAGIO, BBIO, CAPR, COGT
- DHR Q3 Earnings Beat on Biotechnology Strength, Sales in LineNasdaqDHR, BDX, ACHC, AGIO
Agios Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| BRVEBraveheart Bio Inc. | 20.39 | +5.81% | $1.67B | vs AGIO |
| RAREUltragenyx Pharmaceutical Inc. | 16.48 | -4.30% | $1.68B | vs AGIO |
| ZBIOZenas BioPharma Inc. | 23.85 | -4.75% | $1.62B | vs AGIO |
| KRSAKorsana Biosciences Inc. | 37.56 | +5.95% | $1.71B | vs AGIO |
| SDGRSchrodinger Inc. | 22.93 | -12.95% | $1.72B | vs AGIO |
| ANIPANI Pharmaceuticals Inc. | 68.55 | -0.84% | $1.56B | vs AGIO |
| TRAXFirst Tracks Biotherapeutics Inc. | 41.64 | -6.34% | $1.75B | vs AGIO |
| STOKStoke Therapeutics Inc. | 26.81 | -0.45% | $1.75B | vs AGIO |
Indexes, lists and sector
Agios Pharmaceuticals stock FAQ
What is Agios Pharmaceuticals's stock price today?
AGIO last traded at $27.60 as of Nov 20, 4:00 PM EST, down 4.03% on the day. Prices are delayed at least 15 minutes.
Who is Agios Pharmaceuticals's CEO?
Mr. Brian M. Goff M.B.A. is the chief executive officer of Agios Pharmaceuticals Inc., which has about 539 employees.
What is the AGIO 52-week high?
The 52-week high for AGIO is $44.09 and the 52-week low is $24.16. The stock is currently 37.4% below its high.